Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Cash from Operations (2016 - 2025)

Spyre Therapeutics (SYRE) has disclosed Cash from Operations for 11 consecutive years, with 44578000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Operations fell 19.84% year-over-year to 44578000.0, compared with a TTM value of 169252000.0 through Dec 2025, down 7.52%, and an annual FY2025 reading of 169252000.0, down 7.52% over the prior year.
  • Cash from Operations was 44578000.0 for Q4 2025 at Spyre Therapeutics, down from 37117000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 2082000.0 in Q2 2021 and bottomed at 62248000.0 in Q2 2024.
  • Average Cash from Operations over 5 years is 28021600.0, with a median of 27402500.0 recorded in 2022.
  • The sharpest move saw Cash from Operations surged 110.72% in 2021, then crashed 1092.94% in 2022.
  • Year by year, Cash from Operations stood at 19268000.0 in 2021, then grew by 5.85% to 18140000.0 in 2022, then plummeted by 71.09% to 31036000.0 in 2023, then dropped by 19.86% to 37199000.0 in 2024, then fell by 19.84% to 44578000.0 in 2025.
  • Business Quant data shows Cash from Operations for SYRE at 44578000.0 in Q4 2025, 37117000.0 in Q3 2025, and 46563000.0 in Q2 2025.